Gilenya® data at ACTRIMS-ECTRIMS to show Novartis is redefining MS treatment goals for patients

Novartis International AG / Gilenya® data at ACTRIMS-ECTRIMS to show Novartis is redefining MS treatment goals for patients . Processed and transmitted by NASDAQ OMX Corporate Solutions. The issuer is solely responsible for the content of this announcement.

• 'No evidence of disease activity' (NEDA), the ultimate treatment goal in MS, is currently assessed by measuring relapses, MRI lesions and disability progression
   

New Gilenya data will highlight importance of brain shrinkage as NEDA fourth key measure, giving physicians more complete assessment of MS disease in patients
 

Separate analyses will confirm the clinical relevance of brain shrinkage based on its association with future long-term MS disability progression

Basel, Sept 3, 2014 - Novartis announced today that new analyses to be presented at the Joint ACTRIMS-ECTRIMS Meeting in Boston, USA from September 10-13, 2014, will add to the growing evidence confirming the importance of redefining treatment goals in multiple sclerosis (MS). The goal of MS treatment is to have 'no evidence of disease activity' or 'NEDA', which is currently defined as no evidence of relapses, MRI lesions and disability progression. New data to be presented will reinforce the clinical relevance of brain shrinkage (brain volume loss) and highlight the benefit of including it as a fourth key measure of MS in the definition of NEDA[1],[2]. In addition, other analyses will show that patients treated with Gilenya^® (fingolimod) were more likely to achieve NEDA based on assessment of these four key measures, including MS-related brain shrinkage, than those on placebo[3].

Everyone's brain shrinks as they age, but people with MS experience brain shrinkage up to three to five times faster[4-7].  Brain shrinkage begins early in MS, even before symptoms occur[8-11], and is associated with a loss of physical and cognitive function[12].

New Gilenya analyses will show how brain shrinkage is associated with future long-term disability progression in patients with MS and that patients with relapsing MS treated with Gilenya had lower rates of brain shrinkage that importantly were sustained over time[3]. The findings will also provide further evidence of the high efficacy of Gilenya on MS disease activity across four key measures[3].

"The data at ACTRIMS-ECTRIMS will reinforce the role of brain shrinkage and its association with future long-term MS disability progression," said Vasant Narasimhan, Global Head of Development at Novartis Pharmaceuticals, "Novartis is committed to improving treatment outcomes for people with MS, and we believe that by including brain shrinkage as part of NEDA, clinicians can gain a more complete understanding of disease progression and treatment effects."